1. At a Glance – The Prescription Looks Strong… But Pricey
Market Cap: ₹1,41,776 Cr
Current Price: ₹4,188
Stock P/E: 61.5
ROCE: 27%
ROE: 26.5%
Debt: ₹2,822 Cr
Q3 FY26 Sales: ₹3,303 Cr
Q3 FY26 PAT: ₹635 Cr
Return (3 months): 14.4%
Torrent Pharma just dropped its Q3 FY26 numbers and the message is clear: margins are healthy, profits are compounding, and the company is playing global chess while others are still playing Ludo. Sales are up 17.6% YoY, profits up 27.6% YoY, and operating margins sitting comfortably at 33%.
But then comes the awkward dinner-table moment: the stock trades at 61.5 times earnings.
Sixty-one.
In an industry where the median P/E is around 27.9.
So the question is simple: are we paying for performance… or for perfection?
Let’s dissect this pharma giant like a surgeon with a scalpel.
2. Introduction – The Pharma Royalty of Chronic Diseases
Torrent Pharma is not your typical “one-molecule wonder” company. It is the flagship of the Torrent Group, which also plays in power and city gas. But in pharma, Torrent is pure business.
It ranks 5th in the Indian Pharmaceutical Market.
It gets 75% of revenues from chronic & sub-chronic therapies.
It has 21 brands in the Top 500 IPM list.
16 brands generate more than ₹100 Cr each.
This is not trial-and-error pharma. This is franchise-driven dominance.
Globally:
- 1st among Indian pharma companies in Brazil
- 1st among Indian pharma companies in Germany
- Ranked 11th among US generic Indian companies
So yes, this isn’t a domestic-only story.
But let’s pause.
If they are already top-ranked across markets… how much runway is left? And how much of that is already priced in at 61x earnings?
3. Business Model – WTF Do They Even Do?
Torrent Pharma operates in two main segments:
1) Branded Generics (74%)
2) Generics (26%)
Branded Generics – The Real Money Maker
This is their bread and butter. They sell medicines under their own brands
